xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

440

KUANetal.

trial. Lancet Oncol . 2016;17(11):1509-1520. https://doi.org/10. 1016/S1470-2045(16)30410-7 1688. Yang Q, Cao SM, Guo L, et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concur rent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer . 2019;119:87-96. https://doi.org/10.1016/j.ejca.2019.07.007 1689. Hong RL, Hsiao CF, Ting LL, et al. Final results of a randomized phase III trial of induction chemotherapy fol lowed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncol ogy Group (TCOG) 1303 Study. Ann Oncol . 2018;29(9):1972 1979. https://doi.org/10.1093/annonc/mdy249 1690. Jin T, Qin WF, Jiang F, et al. Cisplatin and fluo rouracil induction chemotherapy with or without docetaxel in locoregionally advanced nasopharyn geal carcinoma. Transl Oncol . 2019;12(4):633-639. https://doi.org/10.1016/j.tranon.2019.01.002 1691. Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cis platin induction chemotherapy in nasopharyngeal carcinoma. NEngl J Med . 2019;381(12):1124-1135. https://doi.org/10.1056/ NEJMoa1905287 1692. Liu T, Dai S, Zhang H, Zhong X, Ding Z, Ma X. The best choice of induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma: Bayesian network meta-analysis. Head Neck . 2022;44(2):518-529. https://doi.org/10.1002/hed. 26932 1693. Yang Q, Xia L, Lin M, et al. The impact of induc tion chemotherapy on long-term quality of life in patients with locoregionally advanced nasopha ryngeal carcinoma: outcomes from a randomised phase 3 trial. Oral Oncol . 2021;121(105494):105494. https://doi.org/10.1016/j.oraloncology.2021.105494 1694. Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiother apy plus adjuvant chemotherapy versus concurrent chemora diotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol . 2012;13(2):163-171. https://doi. org/10.1016/S1470-2045(11)70320-5 1695. Chen YP, Wang ZX, Chen L, et al. A Bayesian network meta-analysis comparing concurrent chemoradiotherapy fol lowed by adjuvant chemotherapy, concurrent chemoradio therapy alone and radiotherapy alone in patients with locore gionally advanced nasopharyngeal carcinoma. Ann Oncol . 2015;26(1):205-211. https://doi.org/10.1093/annonc/mdu507 1696. Ribassin-Majed L, Marguet S, Lee AWM. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol . 2017;35(5):498-505. 1697. Yan M, Kumachev A, Siu LL, Chan KK. Chemoradiother apy regimens for locoregionally advanced nasopharyngeal carcinoma: a Bayesian network meta-analysis. Eur J Can cer . 2015;51(12):1570-1579. https://doi.org/10.1016/j.ejca.2015. 04.027 1698. Chen YP, Liu X, Zhou Q, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label,

ning in routine practice. Front Oncol . 2020;10(579917):579917. https://doi.org/10.3389/fonc.2020.579917 1676. Lertbutsayanukul C, Prayongrat A, Kannarunimit D, Chakkabat C, Netsawang B, Kitpanit S. A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopha ryngeal carcinoma. Strahlenther Onkol . 2018;194(5):375-385. https://doi.org/10.1007/s00066-017-1251-5 1677. Nishimura Y, Ishikura S, Shibata T. A phase II study of adap tive two-step intensity-modulated radiation therapy (IMRT) with chemotherapy for loco-regionally advanced nasopharyn geal cancer. Int J Clin Oncol . 2020;25(7):1250-1259. 1678. Lee A, Kitpanit S, Chilov M, Langendijk JA, Lu J, Lee NY. A systematic review of proton therapy for the management of nasopharyngeal cancer. Int J Part Ther . 2021;8(1):119-130. https://doi.org/10.14338/IJPT-20-00082.1 1679. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyn geal cancer: phase III randomized Intergroup study 0099. J Clin Oncol . 1998;16(4):1310-1317. https://doi.org/10.1200/JCO. 1998.16.4.1310 1680. Chen QY, Wen YF, Guo L, et al. Concurrent chemoradio therapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst . 2011;103(23):1761-1770. https://doi.org/10.1093/jnci/djr432 1681. Li XY, Chen QY, Sun XS, et al. Ten-year outcomes of survival and toxicity for a phase III randomised trial of concur rent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma. Eur J Cancer . 2019;110:24-31. https://doi.org/10.1016/j.ejca.2018.10.020 1682. Liu F, Jin T, Liu L, Xiang Z, Yan R, Yang H. The role of concur rent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a systematic review and meta-analysis. PLoSOne . 2018;13(3):e0194733. https://doi. org/10.1371/journal.pone.0194733 1683. Tang LL, Guo R, Zhang N, et al. Effect of radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy on survival without disease relapse in patients with low-risk nasopharyn geal carcinoma a randomized clinical trial. JAMA-J Am Med Assoc . 2022;328(8):728-736. https://doi.org/10.1001/jama.2022. 13997 1684. Tang J, Zou GR, Li XW, Su Z, Cao XL, Wang BC. Weekly versus triweekly cisplatin-based concurrent chemoradiother apy for nasopharyngeal carcinoma: a systematic review and pooled analysis. J Cancer . 2021;12(20):6209-6215. https://doi. org/10.7150/jca.62188 1685. You R, Sun R, Hua YJ, et al. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopha ryngeal carcinoma. Int J Cancer . 2017;141(6):1265-1276. https:// doi.org/10.1002/ijc.30819 1686. Yuan C, Xu XH, Chen Z. Combination treatment with antiEGFR monoclonal antibodies in advanced nasopharyn geal carcinoma: a meta-analysis. J BUON . 2015;20(6):1510 1517. 1687. Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemora diotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled